BMPs and Urology Decreased expression of bone morphogenetic protein (BMP) re- ceptor type II correlates with insensitivity to BMP-6 in human re- nal cell carcinoma cells. Clin Cancer Res 2003;9:6046-51. 53. Basic-Jukic N, Radic-Antolic M, Hudolin T, Coric M, Zadro R, Pasini J, et al. Immunolocalization and mRNA expression of bone morphogenetic protein-6 in human clear cell renal carcinoma. Kidney Blood Press Res 2009;32:445-50. 54. Blish KR, Wang W, Willingham MC, Du W, Birse CE, Krishnan SR, et al. A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell 2008;19:457-64. 55. Kim IY, Lee DH, Lee DK, Kim WJ, Kim MM, Morton RA, et al. Restoration of bone morphogenetic protein receptor type II ex- pression leads to a decreased rate of tumor growth in bladder tran- sitional cell carcinoma cell line TSU-Pr1. Cancer Res 2004;64: 7355-60. 56. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, et al. Expression of bone morphogenetic proteins in human pro- static adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-63. 57. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant pro- static tissue. Cancer Res 1997;57:4427-31. 58. Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H. Increased expression of bone morphogenetic pro- tein-7 in bone metastatic prostate cancer. Prostate 2003;54:268- 74. 59. Yuen HF, Chan YP, Cheung WL, Wong YC, Wang X, Chan KW. The prognostic significance of BMP-6 signaling in prostate cancer. Mod Pathol 2008;21:1436-43. 60. Masuda H, Fukabori Y, Nakano K, Shimizu N, Yamanaka H. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate 2004;59:101-6. 61. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, et al. BMP7, a putative regulator 517 of epithelial homeostasis in the human prostate, is a potent in- hibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007;171:1047-57. 62. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, et al. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human pros- tate cancer tissues. Cancer Res 2000;60:2840-4. 63. Sugimoto H, Yang C, LeBleu VS, Soubasakos MA, Giraldo M, Zeisberg M, et al. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 2007;21:256-64. 64. Souza TA, Chen X, Guo Y, Sava P, Zhang J, Hill JJ, et al. Proteomic identification and functional validation of activins and bone mor- phogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 2008;22:2689-702. 65. Natsume T, Tomita S, Iemura S, Kinto N, Yamaguchi A, Ueno N. Interaction between soluble type I receptor for bone morphoge- netic protein and bone morphogenetic protein-4. J Biol Chem 1997;272:11535-40. 66. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin re- ceptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74. 67. Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005;7:509-21. 68. Lee GT, Hong JH, Mueller TJ, Watson JA, Kwak C, Sheen YY, et al. Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells. J Urol 2008;180:2660-7. 69. Hao J, Daleo MA, Murphy CK, Yu PB, Ho JN, Hu J, et al. Dorsomorphin, a selective small molecule inhibitor of BMP sig- naling, promotes cardiomyogenesis in embryonic stem cells. PLoS One 2008;3:e2904. Korean J Urol 2010;51:511-517